



Press release
March 18, 2008

LinkMed and SLS co-invest in ONCOlog Medical

LinkMed's portfolio company ONCOlog Medical is carrying out a new issue of shares worth SEK 25 million, in which LinkMed is investing SEK 5 million. At the same time, SLS Venture is entering as a new partner with an investment of SEK 20 million.

"ONCOlog Medical entered into a number of key agreements last year and received its first order for a patient logistics system for a proton therapy facility, with high probability that more will follow," says LinkMed's CEO, Ingemar Lagerlöf. "Another sign of strength for the company is that the well-reputed SLS Venture is now coming in as an owner."

ONCOlog Medical is issuing new shares at a subscription price of SEK 80, of which SLS Venture is subscribing to 250 000. Following the new issue, LinkMed will own 533 835 shares corresponding to an ownership stake of 48.9 percent in ONCOlog Medical and SLS Venture's ownership stake will be 22.9 percent.

At the year-end 2007, ONCOlog Medical accounted for 10 percent of LinkMed's total portfolio value according to LinkMed's valuation model.

The capital injection from the new issue will be used to finance the further development of the ongoing commercialization and development of ONCOlog Medical's products. The company develops products and system solutions for quality assurance and patient logistics at radiotherapy clinics for cancer treatment. During 2007, ONCOlog Medical received an order worth SEK 12 million for a patient logistics system for a proton therapy facility in Essen, Germany, from IBA (Ion Beam Applications S.A.), one of the largest suppliers in the proton therapy sector.

SLS Venture is one of Scandinavia's leading venture capital companies with a focus on the life science sector. The company manages SEK 2.7 billion in capital and its portfolio includes the following companies: Exiqon A/S, Aerocrine AB, Symphogen A/S, Doxa AB, NeuroNova AB, AdvanDx Inc, Light Sciences Oncology Inc and Metacure Ltd.

For additional information contact: Ingemar Lagerlöf, CEO LinkMed
Tel +46 8 508 939 93

LinkMed develops new life-science companies in collaboration with innovators. By contributing entrepreneurship and capital, LinkMed has created a portfolio of twelve companies, six in drug development and biotechnology and six in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm and the company's largest partners are FastPartner, Koncentra Holding and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.